Information Journal Paper
APA:
Copy. (2017). SYD985, a novel duocarmycinbased HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. GYNECOLOGIC ONCOLOGY, 146(1), 179-186. SID. https://sid.ir/paper/746567/en
Vancouver:
Copy. SYD985, a novel duocarmycinbased HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. GYNECOLOGIC ONCOLOGY[Internet]. 2017;146(1):179-186. Available from: https://sid.ir/paper/746567/en
IEEE:
Copy, “SYD985, a novel duocarmycinbased HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression,” GYNECOLOGIC ONCOLOGY, vol. 146, no. 1, pp. 179–186, 2017, [Online]. Available: https://sid.ir/paper/746567/en